Main > > >OVARIAN CANCER. *

---

DIAG.: Multivariate Index Assay (MIA) 2nd Generation Blood Test.
for women with a pelvic mass who are planned for surgery.
EU Approval Date : 2015. 10.26.
USA Approval Date: 2016. 03.21.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.06.




RECURRENCE: HE4 CMIA in Serum Monitoring
USA Approval Date: 2010. 06.04.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.06.


TREAT.: DoxoRubicin Liposome. Generic.
USA Approval Date: 2017. 05.17.
(*) Company: Dr. Reddy s Laboratories.
UpDate: 2018. 12.06.




TREAT.: NiraParib Capsules.
[RECURRENT (R); BRCA+]
Companion Diagnostics>
>Company : Myriad Genetics Inc
>TradeMark: BRACAnalysis CDx.
PARP Inhibition.
DE Launch Date : 2017. 12.15.
EU Approval Date : 2017. 11.20.
USA Approval Date: 2017. 03.27.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 12.10.




TREAT.: NiraParib Capsules.
[RECURRENT (R); Homologous Recombination
Deficiency (HRD)+].
PARP Inhibition.
Companion Diagnostics>
USA Approval Date: 2019. 10.23.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.13.




TREAT.: OlaParib Tablets.
(METASTATIC; BRCA+).
>Abnormal Inherited BRCA Gene
>Received>3 Prior CT Medicines
Companion Diagnostics>
>Company : Myriad Genetics Inc.
>TradeMark: BRACAnalysis CDx
PARP Inhibition.
CA Approval Date : 2016. 04.
EU Approval Date : 2014. 12.16.
EU Approval Date : 2019. 06.18.>
>1st Line Maintenance Therapy.
JP Approval Date : 2018. 01.19.
JP Approval Date : 2019. 06.19.>
>1st Line Maintenance Therapy.
USA Approval Date: 2014. 12.19.
USA Approval Date: 2018. 12.19.>
>1st-line maintenance therapy
[RECURRENT (R)
Previously Treated with CT.
EU Approval Date : 2014. 12.16.
JP Approval Date : 2018. 01.19.
USA Approval Date: 2014. 12.19.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 11.14.




TREAT.: Olaparib Tablets+BevacizuMAb.
[METASTATIC>HRD+]
Companion Diagnostics>
>USA Approval Date: 2020. 05.11.
USA Approval Date: 2020. 05.11.
(*) Companies; Patents; TradeMarks &
Web-Sites Available on Request.
UpDate: 2020. 09.17.




TREAT.: PacliTaxel Inj.+CarboPlatin
[Pt-Sensitive>RECURRENT (R)]
DK; FI; SE Launch Date: 2020. 01.30.
EU Approval Date : 2018. 11.22.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2020. 12.29.




TREAT.: RucaParib Tablets.
(METASTATIC; BRCA+).
>Abnormal Inherited BRCA Gene
>Received>2 Prior CT Medicines
Companion Diagnostics>
>Company : Foundation Medicine
>TradeMark : FOUNDATIONONE®CDx
>USA Approval Date: 2016. 12.19.
PARP Inhibition.
USA Approval Date: 2016. 12.19.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.06.




TREAT.: RucaParib Tablets.
(Relapsed)
Maintenance TREAT.
EU Approval Date: 2019. 01.24.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 01.25.




TREAT.: TopoTecan for Inj. for IV Use.
Patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy, as a single agent.
USA Initial Approval: 1996.
(*) Company : Novartis.
Patent : Expired
TradeMark: Hycamtin
UpDate: 2018. 12.10.


>OVARIAN CANCER. *'s products
This section has no products